Experience of pemetrexed in maintenance therapy for metastatic lung adenocarcinoma

Lung cancer is among the most common malignant diseases in Russia. In 80–90%, its morphological type is nonsmall cell lung cancer. Stage IV primary advanced lung cancer is diagnosed in 41% of patients. Median overall survival in stage IV patients receiving chemotherapy is 7–12 months. Treatment for...

Descripció completa

Dades bibliogràfiques

Autors principals:	L. Yu. Vladimirova, A. E. Storozhakova, E. A. Kalabanova, P. N. Meshcheryakov, S. V. Oskin, S. N. Kabanov, N. Yu. Samaneva, Ya. V. Svetitskaya, A. V. Tishina
Format:	Artigo
Idioma:	Russo
Publicat:	ANO "Perspective of oncology" 2021-03-01
Col·lecció:	Южно-Российский онкологический журнал
Matèries:	non-small cell lung cancer adenocarcinoma pemetrexed maintenance therapy adverse effects disease stabilization
Accés en línia:	https://www.cancersp.com/jour/article/view/105
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!